Main navigation
- Home
- Epidermal growth factor receptor story
- EGFR in lung cancer
- Importance of EGFR mutation testing
- Obtaining tumour material for EGFR mutation testing
- Performing EGFR mutation testing
- Using test results to make a treatment decision
- Becoming an EGFR mutation testing laboratory
- EGFR resource centre
- Frequently asked questions about EGFR
You are here
- Home
A history of EGFR
Below is a timeline of the major events that have brought about personalised treatment for non-small cell lung cancer:
-
1962 - Stanley Cohen discovers EGF in mice expand
1977 - Identification of EGFR by Cohen expand
1980 - Demonstration that EGFR has intrinsic kinase activity expand
1981 - John Mendelsohn conducts research focusing on EGFR - proposes EGFR as anticancer target expand
1984 - Human EGFR cloned and sequenced expand
Late 1980s - Mounting evidence for EGFR importance expand
1990 - First clinical trial of anti-EGFR agent (monoclonal antibody) confirms mode of action expand
1994 - AstraZeneca discovers new class of EGFR-tyrosine kinase inhibitors expand
2001 - Anti-tumour activity shown in Phase II results expand
2002 - Gefitinib approved for non-small cell lung cancer in Japan expand
2003 - Gefitinib approved for non-small cell lung cancer in US expand
2004 - EGFR-targeting drugs approved for colorectal and lung cancer expand
2004 - Discovery of EGFR mutations - exons 18–21 - linked to sensitivity to gefitinib expand
2004–2006 - Research into EGFR biomarkers widens expand
2006 - Panitumumab approved for colorectal cancer expand
2007 - Results from INTEREST clinical trial expand
2007- DxS develop EGFR29 Mutation Test Kit expand
2008 - Results from the IPASS study expand